Clinical Trial Update: Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease [Phase 3]

View source ↗

Summary

Phase 3 trial assessing liraglutide for metabolic profile in type 2 diabetes with cardiovascular disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Type 2 Diabetes Mellitus

Drugs mentioned

• liraglutide (liraglutide)

Snippet

Sponsor: RWTH Aachen University | Conditions: Type 2 Diabetes, Cardiovascular Diseases | Phase 3 | Status: WITHDRAWN